Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401725 | 0.86 | TSHR (0.36) | BCHEACHEHTR6MEN1POLB | |
| SCHEMBL6401846 | 0.82 | PTPN1 (0.40) | BCHEACHEHTR6MEN1POLB | |
| SCHEMBL28442951 | 0.80 | BCHE (0.33) | BCHEACHEL3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL6405952 | 0.78 | BCHE (0.32) | BCHEACHEL3MBTL1SMN1; SMN2 | |
| SCHEMBL30084506 | 0.78 | BCHE (0.32) | BCHEACHEL3MBTL1SMN1; SMN2 | |
| SCHEMBL6402578 | 0.77 | MEN1 (0.40) | HTR6MEN1POLBKMT2AATM | |
| Hydrochloric Acid SCHEMBL6402500 | 0.75 | BCHE (0.30) | BCHEACHE | |
| SCHEMBL21034907 | 0.75 | L3MBTL1 (0.35) | BCHEACHEL3MBTL1KCNA3 | |
| SCHEMBL20996226 | 0.75 | L3MBTL1 (0.32) | BCHEACHEL3MBTL1KCNA3 | |
| SCHEMBL30084481 | 0.75 | L3MBTL1 (0.32) | BCHEACHEL3MBTL1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844288-B2 | Process for the preparation of ligands for metallogene catalysts | BASELL POLYOLEFINE GMBH (DE) | 2005-01-18 | — | — | US | disclosed |
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | EQUISTAR CHEMICALS, LP | 2003-08-21 | — | — | US | disclosed |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | RESCONI LUIGI (IT) | 2002-11-14 | — | — | US | disclosed |
| US-6423796-B1 | COORDINATION CATALYST | BASEL TECHNOLOGY COMPANY BV (NL) | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | MACF1, SDC1, SDC2 | BCHE 4211/4885ACHE 4508/4885L3MBTL1 1473/4885 |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | SDC1, SDC2, SDC4 | BCHE 4513/4885ACHE 4573/4885L3MBTL1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.